跳至主要内容
临床试验/CTRI/2024/01/061920
CTRI/2024/01/061920已完成3 期

A Prospective, Multi-Arm, Open-Label, Singl-Centre Clinical Study to Evaluate the Safety and Efficacy of Surabhi Saara in Patients with Diabetes, Varicose Veins, PCOD, Ulcers and Acidity - NI

Surabhi Pharmaceuticals0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Arm A ( Diabetes )
  • 1.Patients with Type 1 and Type 2 Diabetes
  • 2.Cases which are already diagnosed and who are on other systems of medicine treatment will also be taken into consideration.
  • Arm B (Varicose Vein)
  • 1.Patients with unilateral and bilateral varicose vein in the lower limbs
  • 2.Diagnosed case of varicose vein in lower limb
  • Arm C (Polycystic Ovarian Disease)
  • 1.Female patients of age between 20-35years
  • 2.USG pelvis showing polycystic ovaries
  • 3.Irregular menstrual cycle: Eight or fewer menstrual cycles in the past year or inter menstrual periods of 45 days or longer
  • Arm D (Mouth ulcers)
  • 1.Patients with sores or erosion in the inner lining of mouth
  • 2.Cases which are already diagnosed and who are on other systems of medicine treatment will also be taken into consideration.
  • Arm E (Acidity)
  • 1.Patients exhibiting signs of Acidity (pH test is done to detect the same)

排除标准

  • Arm A (Diabetes)
  • 1.Pregnant and lactating mothers
  • 2.Severe cases of Diabetes
  • Arm B ( Varicose Vein)
  • 1.Patients with the bleeding disorders
  • Arm C (Polycystic Ovarian Disease)
  • 1.PCOD cases with severe Systemic illness
  • 2.Pregnant and lactating mothers
  • Arm D and Arm E (Mouth ulcers and Acidity)
  • 1.Chronic alcoholics and Habitual Tobacco chewers
  • 2.Subjects with chronic immune diseases like HIV

研究者

发起方
Surabhi Pharmaceuticals

相似试验